Mucosal (e.g., Nasal, Etc.) Patents (Class 424/434)
-
Patent number: 7867508Abstract: Provided are compositions and methods useful for the non-addictive treatment and prevention of upper respiratory conditions in man and animals, e.g., allergic, non-allergic and mixed rhinitis in man or pharyngitis and IAD in horses. Compositions of the invention comprise effective amounts of a suitable nasal decongestant; a suitable corticosteroid; and a suitable anticholinergic agent. The compositions and methods provided are especially useful for long term use in patients with mixed rhinitis and substantially reduce or eliminate the risk of rhinitis medicamentosa. The compositions and methods of treatment provided also eliminate the risk of adverse sequella seen from therapeutic regimens which employ systemic use of decongestants. The compositions provided can further comprise a suitable aromatic and/or a suitable antihistamine and can also comprise optional suitable antimicrobials, cytokine modulators, leukotriene antagonists, cromolyn sodium, or a suitable NDAID agent.Type: GrantFiled: July 27, 2007Date of Patent: January 11, 2011Inventor: C. Steven Smith
-
Patent number: 7858099Abstract: This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these.Type: GrantFiled: August 20, 2007Date of Patent: December 28, 2010Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Gregor Meyers
-
Patent number: 7829616Abstract: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.Type: GrantFiled: June 8, 2009Date of Patent: November 9, 2010Assignee: Syncera, Inc.Inventors: Tadeusz Wellisz, Timothy C. Fisher, Jonathan K. Armstrong, John Cambridge
-
Patent number: 7803404Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.Type: GrantFiled: September 14, 2006Date of Patent: September 28, 2010Assignee: MannKind CorporationInventors: Mark Hokenson, Keith A. Oberg
-
Patent number: 7799337Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.Type: GrantFiled: August 12, 2002Date of Patent: September 21, 2010Inventor: Bruce H. Levin
-
Patent number: 7799344Abstract: Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.Type: GrantFiled: September 14, 2006Date of Patent: September 21, 2010Assignee: MannKind CorporationInventor: Keith A. Oberg
-
Patent number: 7776312Abstract: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1? (HIF-1?). HIF-1? is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury.Type: GrantFiled: October 13, 2006Date of Patent: August 17, 2010Assignee: HealthPartners Research FoundationInventors: William H. Frey, II, Samuel Scott Panter, Leah Ranae Bresin Hanson, Annina Roeytenberg
-
Patent number: 7763268Abstract: The present invention features dual network hydrogels that possess the structural, mechanical, and biological properties required of load bearing three-dimensional support structures.Type: GrantFiled: January 16, 2009Date of Patent: July 27, 2010Assignee: The Research Foundation of State University of New YorkInventors: Weiliam Chen, Lihui Weng
-
Patent number: 7758886Abstract: Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.Type: GrantFiled: April 14, 2005Date of Patent: July 20, 2010Assignee: Pari GmbHInventors: Jurgen Jauernig, Frank-Christophe Lintz, Manfred Keller, Ingo Friedrich
-
Patent number: 7754205Abstract: The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.Type: GrantFiled: May 8, 2002Date of Patent: July 13, 2010Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Patent number: 7754763Abstract: An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc.Type: GrantFiled: April 30, 2004Date of Patent: July 13, 2010Assignee: Zicam, LLCInventor: Tim Clarot
-
Publication number: 20100166825Abstract: Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.Type: ApplicationFiled: March 9, 2010Publication date: July 1, 2010Applicant: XenoPort, Inc.Inventor: Ronald W. Barrett
-
Patent number: 7744913Abstract: Certain embodiments include a method of improvising radiological outcomes by introducing a filler to between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, and administering a dose of radioactivity to at least the first tissue location or the second tissue location. Collagen and hyaluronic acid are examples of fillers. Certain embodiments include a medical device having a biocompatible, biodegradable filler material, wherein the device comprises at least a portion that has a shape that substantially conforms to Denovillier's space between the rectum and prostate. Certain embodiments include a kit, the kit comprising a filler and instructions for placing the filler between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location.Type: GrantFiled: June 24, 2003Date of Patent: June 29, 2010Assignee: Incept, LLCInventor: William R. Noyes
-
Patent number: 7736626Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: June 20, 2007Date of Patent: June 15, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7736627Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: October 22, 2007Date of Patent: June 15, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7714011Abstract: A gelled composition formulated to maintain an active ingredient in association with the nasal membrane for an extended period of time is provided. The gelled composition may be formulated as a decongestant or a sinus discomfort relieving agent. The invention further includes a system and method for applying the gelled composition to the nasal membrane.Type: GrantFiled: September 15, 2003Date of Patent: May 11, 2010Assignee: Zicam, LLCInventors: Tim Clarot, Charles Hensley
-
Patent number: 7695739Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.Type: GrantFiled: January 8, 2007Date of Patent: April 13, 2010Assignee: Elan Pharma International LimitedInventors: Eugene R. Cooper, John A. Bullock, John R. Chippari, John L. Schaefer, Rakesh A. Patel, Rajeev Jain, Joost Strasters, Niels P. Ryde, Stephen B. Ruddy
-
Patent number: 7682628Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.Type: GrantFiled: August 3, 2007Date of Patent: March 23, 2010Assignee: Transcept Pharmaceuticals, Inc.Inventor: Nikhilesh N. Singh
-
Publication number: 20100055152Abstract: A method of and product for reducing the undesirable effects of allergic rhinitis by applying a formulation to a person's nasal region or nostrils. The formulation creates a barrier that prevents airborne allergens from contacting nasal mucous membranes, and at the same time, electrostatically repels or attracts and captures the particulate allergens, and changes their shapes so as to mitigate the effects of allergic rhinitis. The formulation may be made more effective by the addition of an anti-histamine compound.Type: ApplicationFiled: May 14, 2009Publication date: March 4, 2010Applicant: TRUTEK CORPORATIONInventor: Ashok Wahi
-
Patent number: 7670606Abstract: A vaginal care composition is introduced directly into the vagina in the form of an ovule, a cream or an ointment or with a tampon or which is brought into a position outside the vagina on a panty liner. The composition comprises viable Lactobacillus or Bifidobacterium microorganisms, non-viable Saccharomyces cultures, saccharide(s), vitamin A, and zinc.Type: GrantFiled: November 15, 2006Date of Patent: March 2, 2010Inventor: Peter-Hansen Volkmann
-
Patent number: 7666876Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.Type: GrantFiled: March 19, 2002Date of Patent: February 23, 2010Assignees: Vernalis (R&D) Limited, Archimedes Development LimitedInventors: Phillip John Birch, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
-
Patent number: 7662403Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: GrantFiled: January 4, 2006Date of Patent: February 16, 2010Assignee: Archimedes Development LimitedInventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
-
Patent number: 7658945Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.Type: GrantFiled: February 16, 2005Date of Patent: February 9, 2010Assignee: Transcept Pharmaceuticals, Inc.Inventor: Nikhilesh N. Singh
-
Patent number: 7651698Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.Type: GrantFiled: April 25, 2005Date of Patent: January 26, 2010Assignee: Bioalliance PharmaInventors: Jean-Marc Aiache, Dominique Costantini, Christine Chaumont
-
Patent number: 7645442Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.Type: GrantFiled: August 4, 2003Date of Patent: January 12, 2010Assignee: Alexza Pharmaceuticals, Inc.Inventors: Ron L. Hale, Peter M. Lloyd, Amy Lu, Daniel J. Myers, Reynaldo J. Quintana, Joshua D. Rabinowitz, Dennis W. Solas, Soonho Song, Curtis Tom, Martin J. Wensley
-
Publication number: 20100003308Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.Type: ApplicationFiled: February 27, 2009Publication date: January 7, 2010Inventors: Gilles H. TAPOLSKY, David W. OSBORNE
-
Patent number: 7638138Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.Type: GrantFiled: February 21, 2003Date of Patent: December 29, 2009Assignee: Translational Research, Ltd.Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
-
Publication number: 20090304776Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.Type: ApplicationFiled: December 19, 2008Publication date: December 10, 2009Inventors: Totada Shantha, Jessica Shantha, Erica Shantha, Lauren Shantha
-
Patent number: 7615539Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: GrantFiled: September 27, 2004Date of Patent: November 10, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Patent number: 7615235Abstract: The invention relates to thin film-shaped or wafer-shaped pharmaceutical preparations for oral administration of active substances. The preparations contain at least one matrix-forming polymer which has at least one active substance and at least one carbon dioxide-forming substance dissolved or dispersed therein.Type: GrantFiled: February 4, 2003Date of Patent: November 10, 2009Assignee: LTS Lohmann Therapie-Systeme AGInventors: Tina Rademacher, Frank Seibertz, Petra Brandt, Christian Von Falkenhausen, Markus Krumme
-
Patent number: 7601337Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.Type: GrantFiled: July 18, 2006Date of Patent: October 13, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7596836Abstract: A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution's components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution include: specially denatured alcohol (SDA); Triton x-100; sodium saccharin; 1,8 cineole (eucalyptol); thymol; methyl salicylate; menthol; sorbitol and/or glycerin; sodium benzoate; poloxamer 407; polysorbate 80; and distilled water. Optionally, the solution also includes one or more of the following: citric acid; sambucus nigra agglutinin; a lectin that binds 2,3 sialic acid; nonoxynol-9; sialyllactose; a protease; a protease inhibitor; and/or chloroquine. The solution is applied to the nasal cavity via a pre-moistened cotton swab or a pre-moistened facial tissue and the solution is applied to the back of the throat via a spray, gum, or gargle solution.Type: GrantFiled: May 2, 2007Date of Patent: October 6, 2009Inventor: Steve W. Schwartz
-
Publication number: 20090238859Abstract: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.Type: ApplicationFiled: June 6, 2009Publication date: September 24, 2009Applicant: Sinexus, Inc.Inventors: Donald J. EATON, Mary Lynn Moran, Rodney A. Brenneman
-
Patent number: 7591999Abstract: According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided.Type: GrantFiled: March 4, 2004Date of Patent: September 22, 2009Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takahiro Matsuyama, Hiroyuki Yoshino
-
Patent number: 7585493Abstract: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and 20 ?m. The film thickness is such that an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized compound contains 10% or less drug-degradation product and at least 50% of the total amount of drug composition contained in the film. The selected substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol. Also disclosed are methods of making and using the article.Type: GrantFiled: August 4, 2003Date of Patent: September 8, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Ron L. Hale, Amy Lu, Daniel J. Myers, Joshua D. Rabinowitz, Martin J. Wensley
-
Patent number: 7585519Abstract: Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.Type: GrantFiled: March 27, 2007Date of Patent: September 8, 2009Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Pisano, Maria Ornella Tinti, Mosé Santaniello, Luciana Critelli, Giovanni Salvatori
-
Patent number: 7582284Abstract: The present invention relates to active substances in particulate form, to methods for preparing them, to formulations containing them and to uses of such substances and formulations. A preferred embodiment is directed to particulate suspensions having improved flocculation behavior in a suspension vehicle, such as a hydrofluoroalkane propellant used in metered dose inhalers.Type: GrantFiled: April 14, 2003Date of Patent: September 1, 2009Assignee: Nektar TherapeuticsInventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
-
Publication number: 20090208551Abstract: The present invention relates to a biological implantation material and method of preparing the same, which comprises the steps of: (i) treating a tissue derived from animal or human with alcohol; (ii) contacting the said tissue with an enzyme selected from the group consisting of dispase, DNAse, RNAse and pepsin in a solvent; (iii) treating the tissue obtained in step (ii) with alkaline solution; and (iv) treating the tissue obtained in step (iii) with acid solution.Type: ApplicationFiled: July 10, 2008Publication date: August 20, 2009Applicant: BIOLAND LTD.Inventors: In Seop Kim, Dae Gu Son, Young Chul Jang, Eun Kyung Yang, Sung Po Kim, Jong Myoung Hong, Ji Hoon Joo, Jong Sang Kim, Sam Hyun Jung, Jong Won Lee, Mi Young Kwon
-
Patent number: 7563464Abstract: A composition and method for direct application to mucosal membranes, which combines naturally occurring phytoestrogens, such as plant extracts and soy isoflavones, with other active and inactive ingredients in a convenient medium, such as an aqueous cream, aqueous spray or suppository. The composition may be used for the treatment of dry or inadequately hydrated mucosal surfaces, and related complications, such as those affecting the nasal passages or vagina.Type: GrantFiled: October 30, 2007Date of Patent: July 21, 2009Inventors: Bruce Eric Hudkins, Thomas G. Matkov
-
Patent number: 7553913Abstract: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homo-polymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.Type: GrantFiled: February 12, 2004Date of Patent: June 30, 2009Assignee: Syncera, Inc.Inventors: Tadeusz Wellisz, Timothy C. Fisher, Jonathan K. Armstrong, John Cambridge
-
Patent number: 7550133Abstract: Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of ?-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment.Type: GrantFiled: November 20, 2003Date of Patent: June 23, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Ron L. Hale, Peter M. Lloyd, Amy T. Lu, Joshua D. Rabinowitz, Martin J. Wensley
-
Patent number: 7524828Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant.Type: GrantFiled: August 18, 2004Date of Patent: April 28, 2009Assignee: University of Iowa Research FoundationInventors: Arthur M. Krieg, Joel N. Kline
-
Patent number: 7524484Abstract: The present invention relates to the delivery of diphenhydramine through an inhalation route. In a composition aspect of the present invention, a composition of a diphenhydramine condensation aerosol is presented. In a method aspect of the present invention, diphenhydramine aerosol is formed by: a) heating a thin layer of diphenhydramine on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% degradation product and an aerosol having an MMAD less than 3 microns. In a kit aspect of the present invention, a kit for delivering a condensation aerosol is provided which comprises: a) a thin coating of diphenhydramine; and b) a device for dispensing the diphenhydramine as an aerosol.Type: GrantFiled: June 30, 2006Date of Patent: April 28, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7517861Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: GrantFiled: July 9, 2004Date of Patent: April 14, 2009Assignee: University of Iowa Research FoundationInventors: Arthur M. Krieg, Joel N. Kline
-
Patent number: 7510702Abstract: The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention, an NSAID is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of an NSAID, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particle having less than 5% NSAID degradation products. In a kit aspect of the present invention, a kit for delivering an NSAID through an inhalation route is provided which comprises: a) a coating of an NSAID composition and b) a device for dispensing said coating as a condensation aerosol.Type: GrantFiled: August 7, 2006Date of Patent: March 31, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7507398Abstract: The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a method aspect of the present invention, the physiologically active compound is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a physiologically active compound, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% physiologically active compound degradation products. In a kit aspect of the present invention, a kit for delivering a physiologically active compound through an inhalation route is provided which comprises: a) a thin coating of a physiologically active compound, and b) a device for dispensing said thin coating as a condensation aerosol.Type: GrantFiled: June 30, 2006Date of Patent: March 24, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Joshua D Rabinowitz, Alejandro C Zaffaroni
-
Patent number: 7498019Abstract: The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.Type: GrantFiled: March 21, 2006Date of Patent: March 3, 2009Assignee: Alexza Pharmaceuticals, Inc.Inventors: Ron L. Hale, Joshua D. Rabinowitz, Dennis W. Solas, Alejandro C. Zaffaroni
-
Patent number: RE40812Abstract: A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration. A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof.Type: GrantFiled: February 5, 2004Date of Patent: June 30, 2009Assignee: Unigene Laboratories Inc.Inventor: William Stern
-
Patent number: RE41996Abstract: Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The composition also include, or are administered in conjunction with, an enhancer in an amount effective to maximize expression of or binding to receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents. Compositions are applied topically orally, nasally, vaginally, rectally, and ocularly. The enhancer is administered with the composition or separately, either systemically or preferably locally. The compound to be delivered can also be the enhancer.Type: GrantFiled: June 21, 2007Date of Patent: December 14, 2010Assignee: The Penn State Research Foundation Massachusetts Institute of TechnologyInventors: Daniel R. Deaver, David A. Edwards, Robert S. Langer
-
Patent number: RE42012Abstract: Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The composition also include, or are administered in conjunction with, an enhancer in an amount effective to maximize expression of or binding to receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents. Compositions are applied topically orally, nasally, vaginally, rectally, and ocularly. The enhancer is administered with the composition or separately, either systemically or preferably locally. The compound to be delivered can also be the enhancer.Type: GrantFiled: June 21, 2007Date of Patent: December 28, 2010Assignees: The Penn State Research Foundation, Massachusetts Institute of TechnologyInventors: Daniel R. Deaver, David A. Edwards, Robert S. Langer